Global Vagal Nerve Stimulators

Vagal Nerve Stimulators Comprehensive Study by Type (Implantable VNS Device, Non-invasive VNS Device), Application (Pain Management, Epileptic Seizures, Obesity Management, Depression, Anxiety, Others), Patient Type (Adults, Pediatrics, Geriatrics), End User (Hospital, Ambulatory Surgery Centre, Specialty Hospital, Others) Players and Region - Global Market Outlook to 2030

Vagal Nerve Stimulators Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 10.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Vagal Nerve Stimulators
A procedure in which a device similar to a heart pacemaker is implanted under the skin. It sends regular impulses of electrical energy to the brain through the vagus nerve to prevent or reduce seizures. VNS can improve an individual’s physical health and can offer benefits for several conditions. The treatment has a healing effect on a person’s body due to its ability to promote relaxation and reduce inflammation. People most commonly use VNS to treat epilepsy and depression.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR10.1%


Competition among existing players is due to the vagal nerve stimulation market share occupied by leading players. The industry leader is engaged in offering innovative and superior quality products to cater to the ever-growing demand for vagal nerve stimulation Market. The companies are implementing strategic activities such as acquisitions and mergers along with collaboration with companies in other industries to aid them in improving sustenance and maintaining their competitive advantage. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Vagal Nerve Stimulators market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

ReShape Lifesciences Inc. (United States), ElectroCore Medical LLC (United States), Boston Scientific Corporation (United States), Medtronic (Ireland), ImThera Medical, Inc. (United States), Inspire Medical Systems, Inc. (United States), Parasym Ltd (United Kingdom), Innovative Health Solutions, Inc. (United States), Cerbomed GMBH (Germany), Soterix Medical Inc. (United States) and MicroTransponder Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Brain Control Co. (United Kingdom), SetPoint Medical (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Vagal Nerve Stimulators market by Type (Implantable VNS Device and Non-invasive VNS Device), Application (Pain Management, Epileptic Seizures, Obesity Management, Depression, Anxiety and Others) and Region.



On the basis of geography, the market of Vagal Nerve Stimulators has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Patient Type, the sub-segment i.e. Adults will boost the Vagal Nerve Stimulators market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital will boost the Vagal Nerve Stimulators market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing number of neurological disorders. and Increasing investment in research and development for vagal nerve stimulation.

Market Growth Drivers:
Growing incidence of neurological disorder such as epilepsy, depression and migraine. and The rising adoption of minimally invasive neurosurgical procedures.

Challenges:
Stringent regulation and time consuming approval processes for neurostimulation.

Restraints:
High device cost. and Limited availability of skilled professionals.

Opportunities:
Technological advancement in VNS devices. and Rapid increase in cases of depression.

Market Leaders and their expansionary development strategies
In September 2023, Boston Scientific Corporation, announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain. The transaction includes an upfront cash payment of USD 850 million and undisclosed additional contingent payments based on sales performance over the next three years. Acquisition intended to expand neuromodulation portfolio to provide more treatment options for people living with chronic low back pain.
In February 2023, Medical technology company LivaNova has launched SenTiva DUO, a new implantable pulse generator (IPG). Featuring a dual-pin head, the new IPG is designed to provide Vagus Nerve Stimulation (VNS) therapy for drug-resistant epilepsy treatment.


Key Target Audience
Manufacturers Suppliers and Distributors, Venture Capitalists and Private Equity Firms, New Entrants/Investors, Strategic Business Planners, Government Regulatory, Research Organizations, End-Use Industries and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Implantable VNS Device
  • Non-invasive VNS Device
By Application
  • Pain Management
  • Epileptic Seizures
  • Obesity Management
  • Depression
  • Anxiety
  • Others
By Patient Type
  • Adults
  • Pediatrics
  • Geriatrics

By End User
  • Hospital
  • Ambulatory Surgery Centre
  • Specialty Hospital
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing incidence of neurological disorder such as epilepsy, depression and migraine.
      • 3.2.2. The rising adoption of minimally invasive neurosurgical procedures.
    • 3.3. Market Challenges
      • 3.3.1. Stringent regulation and time consuming approval processes for neurostimulation.
    • 3.4. Market Trends
      • 3.4.1. Increasing number of neurological disorders.
      • 3.4.2. Increasing investment in research and development for vagal nerve stimulation.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Vagal Nerve Stimulators, by Type, Application, Patient Type, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Vagal Nerve Stimulators (Value)
      • 5.2.1. Global Vagal Nerve Stimulators by: Type (Value)
        • 5.2.1.1. Implantable VNS Device
        • 5.2.1.2. Non-invasive VNS Device
      • 5.2.2. Global Vagal Nerve Stimulators by: Application (Value)
        • 5.2.2.1. Pain Management
        • 5.2.2.2. Epileptic Seizures
        • 5.2.2.3. Obesity Management
        • 5.2.2.4. Depression
        • 5.2.2.5. Anxiety
        • 5.2.2.6. Others
      • 5.2.3. Global Vagal Nerve Stimulators by: Patient Type (Value)
        • 5.2.3.1. Adults
        • 5.2.3.2. Pediatrics
        • 5.2.3.3. Geriatrics
      • 5.2.4. Global Vagal Nerve Stimulators by: End User (Value)
        • 5.2.4.1. Hospital
        • 5.2.4.2. Ambulatory Surgery Centre
        • 5.2.4.3. Specialty Hospital
        • 5.2.4.4. Others
      • 5.2.5. Global Vagal Nerve Stimulators Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Vagal Nerve Stimulators: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. ReShape Lifesciences Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ElectroCore Medical LLC (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boston Scientific Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Medtronic (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. ImThera Medical, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Inspire Medical Systems, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Parasym Ltd (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Innovative Health Solutions, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cerbomed GMBH (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Soterix Medical Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. MicroTransponder Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Vagal Nerve Stimulators Sale, by Type, Application, Patient Type, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Vagal Nerve Stimulators (Value)
      • 7.2.1. Global Vagal Nerve Stimulators by: Type (Value)
        • 7.2.1.1. Implantable VNS Device
        • 7.2.1.2. Non-invasive VNS Device
      • 7.2.2. Global Vagal Nerve Stimulators by: Application (Value)
        • 7.2.2.1. Pain Management
        • 7.2.2.2. Epileptic Seizures
        • 7.2.2.3. Obesity Management
        • 7.2.2.4. Depression
        • 7.2.2.5. Anxiety
        • 7.2.2.6. Others
      • 7.2.3. Global Vagal Nerve Stimulators by: Patient Type (Value)
        • 7.2.3.1. Adults
        • 7.2.3.2. Pediatrics
        • 7.2.3.3. Geriatrics
      • 7.2.4. Global Vagal Nerve Stimulators by: End User (Value)
        • 7.2.4.1. Hospital
        • 7.2.4.2. Ambulatory Surgery Centre
        • 7.2.4.3. Specialty Hospital
        • 7.2.4.4. Others
      • 7.2.5. Global Vagal Nerve Stimulators Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Vagal Nerve Stimulators: by Type(USD Million)
  • Table 2. Vagal Nerve Stimulators Implantable VNS Device , by Region USD Million (2018-2023)
  • Table 3. Vagal Nerve Stimulators Non-invasive VNS Device , by Region USD Million (2018-2023)
  • Table 4. Vagal Nerve Stimulators: by Application(USD Million)
  • Table 5. Vagal Nerve Stimulators Pain Management , by Region USD Million (2018-2023)
  • Table 6. Vagal Nerve Stimulators Epileptic Seizures , by Region USD Million (2018-2023)
  • Table 7. Vagal Nerve Stimulators Obesity Management , by Region USD Million (2018-2023)
  • Table 8. Vagal Nerve Stimulators Depression , by Region USD Million (2018-2023)
  • Table 9. Vagal Nerve Stimulators Anxiety , by Region USD Million (2018-2023)
  • Table 10. Vagal Nerve Stimulators Others , by Region USD Million (2018-2023)
  • Table 11. Vagal Nerve Stimulators: by Patient Type(USD Million)
  • Table 12. Vagal Nerve Stimulators Adults , by Region USD Million (2018-2023)
  • Table 13. Vagal Nerve Stimulators Pediatrics , by Region USD Million (2018-2023)
  • Table 14. Vagal Nerve Stimulators Geriatrics , by Region USD Million (2018-2023)
  • Table 15. Vagal Nerve Stimulators: by End User(USD Million)
  • Table 16. Vagal Nerve Stimulators Hospital , by Region USD Million (2018-2023)
  • Table 17. Vagal Nerve Stimulators Ambulatory Surgery Centre , by Region USD Million (2018-2023)
  • Table 18. Vagal Nerve Stimulators Specialty Hospital , by Region USD Million (2018-2023)
  • Table 19. Vagal Nerve Stimulators Others , by Region USD Million (2018-2023)
  • Table 20. South America Vagal Nerve Stimulators, by Country USD Million (2018-2023)
  • Table 21. South America Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 22. South America Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 23. South America Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 24. South America Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 25. Brazil Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 26. Brazil Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 27. Brazil Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 28. Brazil Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 29. Argentina Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 30. Argentina Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 31. Argentina Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 32. Argentina Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 33. Rest of South America Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 34. Rest of South America Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 35. Rest of South America Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 36. Rest of South America Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 37. Asia Pacific Vagal Nerve Stimulators, by Country USD Million (2018-2023)
  • Table 38. Asia Pacific Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 39. Asia Pacific Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 40. Asia Pacific Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 41. Asia Pacific Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 42. China Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 43. China Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 44. China Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 45. China Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 46. Japan Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 47. Japan Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 48. Japan Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 49. Japan Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 50. India Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 51. India Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 52. India Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 53. India Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 54. South Korea Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 55. South Korea Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 56. South Korea Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 57. South Korea Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 58. Taiwan Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 59. Taiwan Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 60. Taiwan Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 61. Taiwan Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 62. Australia Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 63. Australia Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 64. Australia Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 65. Australia Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 70. Europe Vagal Nerve Stimulators, by Country USD Million (2018-2023)
  • Table 71. Europe Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 72. Europe Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 73. Europe Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 74. Europe Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 75. Germany Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 76. Germany Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 77. Germany Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 78. Germany Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 79. France Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 80. France Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 81. France Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 82. France Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 83. Italy Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 84. Italy Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 85. Italy Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 86. Italy Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 87. United Kingdom Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 88. United Kingdom Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 89. United Kingdom Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 90. United Kingdom Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 91. Netherlands Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 92. Netherlands Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 93. Netherlands Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 94. Netherlands Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 95. Rest of Europe Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 96. Rest of Europe Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 97. Rest of Europe Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 98. Rest of Europe Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 99. MEA Vagal Nerve Stimulators, by Country USD Million (2018-2023)
  • Table 100. MEA Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 101. MEA Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 102. MEA Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 103. MEA Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 104. Middle East Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 105. Middle East Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 106. Middle East Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 107. Middle East Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 108. Africa Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 109. Africa Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 110. Africa Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 111. Africa Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 112. North America Vagal Nerve Stimulators, by Country USD Million (2018-2023)
  • Table 113. North America Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 114. North America Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 115. North America Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 116. North America Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 117. United States Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 118. United States Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 119. United States Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 120. United States Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 121. Canada Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 122. Canada Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 123. Canada Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 124. Canada Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 125. Mexico Vagal Nerve Stimulators, by Type USD Million (2018-2023)
  • Table 126. Mexico Vagal Nerve Stimulators, by Application USD Million (2018-2023)
  • Table 127. Mexico Vagal Nerve Stimulators, by Patient Type USD Million (2018-2023)
  • Table 128. Mexico Vagal Nerve Stimulators, by End User USD Million (2018-2023)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Vagal Nerve Stimulators: by Type(USD Million)
  • Table 141. Vagal Nerve Stimulators Implantable VNS Device , by Region USD Million (2025-2030)
  • Table 142. Vagal Nerve Stimulators Non-invasive VNS Device , by Region USD Million (2025-2030)
  • Table 143. Vagal Nerve Stimulators: by Application(USD Million)
  • Table 144. Vagal Nerve Stimulators Pain Management , by Region USD Million (2025-2030)
  • Table 145. Vagal Nerve Stimulators Epileptic Seizures , by Region USD Million (2025-2030)
  • Table 146. Vagal Nerve Stimulators Obesity Management , by Region USD Million (2025-2030)
  • Table 147. Vagal Nerve Stimulators Depression , by Region USD Million (2025-2030)
  • Table 148. Vagal Nerve Stimulators Anxiety , by Region USD Million (2025-2030)
  • Table 149. Vagal Nerve Stimulators Others , by Region USD Million (2025-2030)
  • Table 150. Vagal Nerve Stimulators: by Patient Type(USD Million)
  • Table 151. Vagal Nerve Stimulators Adults , by Region USD Million (2025-2030)
  • Table 152. Vagal Nerve Stimulators Pediatrics , by Region USD Million (2025-2030)
  • Table 153. Vagal Nerve Stimulators Geriatrics , by Region USD Million (2025-2030)
  • Table 154. Vagal Nerve Stimulators: by End User(USD Million)
  • Table 155. Vagal Nerve Stimulators Hospital , by Region USD Million (2025-2030)
  • Table 156. Vagal Nerve Stimulators Ambulatory Surgery Centre , by Region USD Million (2025-2030)
  • Table 157. Vagal Nerve Stimulators Specialty Hospital , by Region USD Million (2025-2030)
  • Table 158. Vagal Nerve Stimulators Others , by Region USD Million (2025-2030)
  • Table 159. South America Vagal Nerve Stimulators, by Country USD Million (2025-2030)
  • Table 160. South America Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 161. South America Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 162. South America Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 163. South America Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 164. Brazil Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 165. Brazil Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 166. Brazil Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 167. Brazil Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 168. Argentina Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 169. Argentina Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 170. Argentina Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 171. Argentina Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 172. Rest of South America Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 173. Rest of South America Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 174. Rest of South America Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 175. Rest of South America Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 176. Asia Pacific Vagal Nerve Stimulators, by Country USD Million (2025-2030)
  • Table 177. Asia Pacific Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 178. Asia Pacific Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 179. Asia Pacific Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 180. Asia Pacific Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 181. China Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 182. China Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 183. China Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 184. China Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 185. Japan Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 186. Japan Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 187. Japan Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 188. Japan Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 189. India Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 190. India Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 191. India Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 192. India Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 193. South Korea Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 194. South Korea Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 195. South Korea Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 196. South Korea Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 197. Taiwan Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 198. Taiwan Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 199. Taiwan Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 200. Taiwan Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 201. Australia Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 202. Australia Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 203. Australia Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 204. Australia Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 206. Rest of Asia-Pacific Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 207. Rest of Asia-Pacific Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 208. Rest of Asia-Pacific Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 209. Europe Vagal Nerve Stimulators, by Country USD Million (2025-2030)
  • Table 210. Europe Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 211. Europe Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 212. Europe Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 213. Europe Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 214. Germany Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 215. Germany Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 216. Germany Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 217. Germany Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 218. France Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 219. France Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 220. France Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 221. France Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 222. Italy Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 223. Italy Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 224. Italy Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 225. Italy Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 226. United Kingdom Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 227. United Kingdom Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 228. United Kingdom Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 229. United Kingdom Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 230. Netherlands Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 231. Netherlands Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 232. Netherlands Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 233. Netherlands Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 234. Rest of Europe Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 235. Rest of Europe Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 236. Rest of Europe Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 237. Rest of Europe Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 238. MEA Vagal Nerve Stimulators, by Country USD Million (2025-2030)
  • Table 239. MEA Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 240. MEA Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 241. MEA Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 242. MEA Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 243. Middle East Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 244. Middle East Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 245. Middle East Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 246. Middle East Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 247. Africa Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 248. Africa Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 249. Africa Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 250. Africa Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 251. North America Vagal Nerve Stimulators, by Country USD Million (2025-2030)
  • Table 252. North America Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 253. North America Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 254. North America Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 255. North America Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 256. United States Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 257. United States Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 258. United States Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 259. United States Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 260. Canada Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 261. Canada Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 262. Canada Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 263. Canada Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 264. Mexico Vagal Nerve Stimulators, by Type USD Million (2025-2030)
  • Table 265. Mexico Vagal Nerve Stimulators, by Application USD Million (2025-2030)
  • Table 266. Mexico Vagal Nerve Stimulators, by Patient Type USD Million (2025-2030)
  • Table 267. Mexico Vagal Nerve Stimulators, by End User USD Million (2025-2030)
  • Table 268. Research Programs/Design for This Report
  • Table 269. Key Data Information from Secondary Sources
  • Table 270. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Vagal Nerve Stimulators: by Type USD Million (2018-2023)
  • Figure 5. Global Vagal Nerve Stimulators: by Application USD Million (2018-2023)
  • Figure 6. Global Vagal Nerve Stimulators: by Patient Type USD Million (2018-2023)
  • Figure 7. Global Vagal Nerve Stimulators: by End User USD Million (2018-2023)
  • Figure 8. South America Vagal Nerve Stimulators Share (%), by Country
  • Figure 9. Asia Pacific Vagal Nerve Stimulators Share (%), by Country
  • Figure 10. Europe Vagal Nerve Stimulators Share (%), by Country
  • Figure 11. MEA Vagal Nerve Stimulators Share (%), by Country
  • Figure 12. North America Vagal Nerve Stimulators Share (%), by Country
  • Figure 13. Global Vagal Nerve Stimulators share by Players 2023 (%)
  • Figure 14. Global Vagal Nerve Stimulators share by Players (Top 3) 2023(%)
  • Figure 15. Global Vagal Nerve Stimulators share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. ReShape Lifesciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. ReShape Lifesciences Inc. (United States) Revenue: by Geography 2023
  • Figure 19. ElectroCore Medical LLC (United States) Revenue, Net Income and Gross profit
  • Figure 20. ElectroCore Medical LLC (United States) Revenue: by Geography 2023
  • Figure 21. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 22. Boston Scientific Corporation (United States) Revenue: by Geography 2023
  • Figure 23. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 24. Medtronic (Ireland) Revenue: by Geography 2023
  • Figure 25. ImThera Medical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. ImThera Medical, Inc. (United States) Revenue: by Geography 2023
  • Figure 27. Inspire Medical Systems, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Inspire Medical Systems, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Parasym Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. Parasym Ltd (United Kingdom) Revenue: by Geography 2023
  • Figure 31. Innovative Health Solutions, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Innovative Health Solutions, Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Cerbomed GMBH (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Cerbomed GMBH (Germany) Revenue: by Geography 2023
  • Figure 35. Soterix Medical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Soterix Medical Inc. (United States) Revenue: by Geography 2023
  • Figure 37. MicroTransponder Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. MicroTransponder Inc. (United States) Revenue: by Geography 2023
  • Figure 39. Global Vagal Nerve Stimulators: by Type USD Million (2025-2030)
  • Figure 40. Global Vagal Nerve Stimulators: by Application USD Million (2025-2030)
  • Figure 41. Global Vagal Nerve Stimulators: by Patient Type USD Million (2025-2030)
  • Figure 42. Global Vagal Nerve Stimulators: by End User USD Million (2025-2030)
  • Figure 43. South America Vagal Nerve Stimulators Share (%), by Country
  • Figure 44. Asia Pacific Vagal Nerve Stimulators Share (%), by Country
  • Figure 45. Europe Vagal Nerve Stimulators Share (%), by Country
  • Figure 46. MEA Vagal Nerve Stimulators Share (%), by Country
  • Figure 47. North America Vagal Nerve Stimulators Share (%), by Country
List of companies from research coverage that are profiled in the study
  • ReShape Lifesciences Inc. (United States)
  • ElectroCore Medical LLC (United States)
  • Boston Scientific Corporation (United States)
  • Medtronic (Ireland)
  • ImThera Medical, Inc. (United States)
  • Inspire Medical Systems, Inc. (United States)
  • Parasym Ltd (United Kingdom)
  • Innovative Health Solutions, Inc. (United States)
  • Cerbomed GMBH (Germany)
  • Soterix Medical Inc. (United States)
  • MicroTransponder Inc. (United States)
Additional players considered in the study are as follows:
Brain Control Co. (United Kingdom) , SetPoint Medical (United States) , Others
Select User Access Type

Key Highlights of Report


Mar 2024 236 Pages 92 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Vagal Nerve Stimulators Quantitative research analysis
Global Vagal Nerve Stimulators Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as ReShape Lifesciences Inc. (United States), ElectroCore Medical LLC (United States), Boston Scientific Corporation (United States), Medtronic (Ireland), ImThera Medical, Inc. (United States), Inspire Medical Systems, Inc. (United States), Parasym Ltd (United Kingdom), Innovative Health Solutions, Inc. (United States), Cerbomed GMBH (Germany), Soterix Medical Inc. (United States) and MicroTransponder Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing number of neurological disorders. " is seen as one of major influencing trends for Vagal Nerve Stimulators Market during projected period 2023-2030.
The Vagal Nerve Stimulators market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Vagal Nerve Stimulators Report?

Have a Query? Click Here

Other Related Reports

Glaucoma Treatment Drugs Comprehensive Study by Type (Oral Drug, Injection Drug), Application (Hospital, Clinic, Home Care), Distribution Channel (Prescription Drugs, Over-the-Counter Drugs), Dosage ...
$ 3350
Idiopathic Pulmonary Fibrosis Comprehensive Study by Application (Hospital, Clinic, Others), Drugs (Systemic corticosteroids, Immunosuppressant drugs, Tyrosine kinase inhibitors, Antifibrotic agents)...
$ 3650
Hypertrophic Cardiomyopathy Therapeutics Comprehensive Study by Type (Anticoagulants Beta-Adrenergic Blocking Agents, Antiarrhythmic Agents, Calcium Channel Blockers, Others), Application (Hospitals,...
$ 3750
Immunodiagnostics Comprehensive Study by Type (Reagents, Instruments, Software & Services), Application (Oncology and Endocrinology, Hepatitis and Retrovirus Testing, Infectious Disease Testing, GI S...
$ 3750
Cancer Stem Cells Comprehensive Study by Type (Cell Culturing, Cell Separation, Cell Analysis, Molecular Analysis, Others), Application (Breast Cancer Diagnosis and Treatment , Prostate Cancer Diagno...
$ 3750
Scar Removal Treatment Comprehensive Study by Type (Surgical Method, Topical Creams, Laser Treatment, Injectable, Others), Application (Keloid Scars, Contracture Scars, Hypertrophic Scars, Acne Scars...
$ 3450